Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab in biomarker-selected high-risk stage II melanoma
2019-002276-13Phase 3Active
- Sponsor
- Universitätsmedizin Essen
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in cutaneous melanoma (CM) comparing Nivolumab with Observation (2 arms). Primary endpoint: Relapse-free survival (RFS) rate. Started Aug 2019; status: active.
02
Drugs
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2019-002276-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002276-13.